063160.KO Ckd Bio
- Market cap
- KRW 64.1B
- P/E
- -
- P/B
- 0.52x
- ROE
- -12.4%
- Dividend yield
- 0.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 063160.KO undervalued?
Graham numberThe Graham number of Ckd Bio cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ckd Bio fundamental analysis
No fundamental analysis for Ckd Bio yet.
Ckd Bio stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seo…
Full company profileCkd Bio financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ckd Bio annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 113B | 118B | 125B | 137B | 125B | 142B | 156B | 160B | 172B | 160B | 164B |
| Gross Profit | 26.4B | 24.9B | 23.4B | 36.2B | 27.9B | 13.3B | 16.8B | 8.01B | 35.9B | 28.8B | 12.5B |
| Operating Income | 11.6B | 9.03B | 7.01B | 15.4B | 7.61B | -11.4B | -14.8B | -20.2B | 11.0B | 3.61B | -13.4B |
| EBITDA | - | 18.9B | 18.4B | 25.6B | 19.9B | 5.56B | 2.29B | -1.63B | 31.2B | 18.3B | 6.08B |
| Net Income | 9.43B | 8.02B | 7.96B | 12.3B | 6.21B | -6.58B | -16.7B | -24.2B | 8.70B | -2.89B | -14.9B |
| EPS | - | 1,488 | 1,477 | 2,391 | 1,132 | -1,199 | -3,045 | -4,410 | 1,586 | -526 | -2,710 |
| Balance Sheet | |||||||||||
| Total Assets | 181B | 179B | 185B | 233B | 283B | 299B | 313B | 294B | 284B | 300B | 293B |
| Total Liabilities | 45.7B | 37.4B | 36.9B | 74.9B | 115B | 137B | 165B | 171B | 153B | 173B | 173B |
| Shareholders' Equity | 135B | 142B | 148B | 158B | 169B | 161B | 148B | 123B | 131B | 127B | 120B |
| Cash & Short-term Investments | 14.9B | 15.7B | 12.0B | 4.49B | 1.46B | 3.47B | 4.66B | 3.63B | 1.09B | 1.43B | 517M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.5B | 20.4B | 15.5B | 17.0B | 4.82B | -5.88B | -3.20B | -7.22B | 14.0B | -4.14B | 6.78B |
| Capital Expenditure | 10.8B | 9.67B | 16.4B | 47.3B | 61.7B | 20.5B | 6.20B | 10.8B | 4.28B | 6.82B | 14.1B |
| Free Cash Flow | - | 10.8B | -1.48B | -31.0B | -57.8B | -26.6B | -10.4B | -18.0B | 9.75B | -11.0B | -7.28B |
| Ratios | |||||||||||
| ROE | 7.0% | 5.6% | 5.4% | 7.7% | 3.7% | -4.1% | -11.3% | -19.7% | 6.6% | -2.3% | -12.4% |
| ROA | 5.2% | 4.5% | 4.3% | 5.3% | 2.2% | -2.2% | -5.3% | -8.2% | 3.1% | -1.0% | -5.1% |
| Net Profit Margin | 8.3% | 6.8% | 6.4% | 8.9% | 5.0% | -4.6% | -10.7% | -15.1% | 5.1% | -1.8% | -9.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ckd Bio dividends
- Dividend yield
- 0.86%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 549M | 100 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | KRW 549M | 100 | - |
| 2021 | KRW 1.10B | 200 | - |
| 2020 | KRW 1.03B | 187 | 16.5% |
| 2019 | KRW 1.03B | 200 | 8.4% |
| 2018 | KRW 2.05B | 381 | 25.8% |
| 2017 | KRW 2.05B | 381 | 25.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Dec 27, 2019.
Who owns Ckd Bio
- Insiders 39.16%
- Institutions 0.04%
- Public & others 60.81%
- Shares outstanding 5.49M
- Free float 3.34M
Ckd Bio company profile
- Company name
- Ckd Bio
- Ticker
- 063160.KO
- ISIN
- KR7063160006
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 519
- Fiscal year end
- December
- Address
- 8 Chungjeong-ro, Seoul, South Korea, 03742
- Phone
- 82 2 2194 0555
- Website
- ckdbio.com
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Ckd Bio management
2- Wan-Kap ParkChief Executive Officer
- Mr. Hui Yil KangVP & Director